PGIM India Large and Mid Cap Fund
The Scheme seeks to seek long term capital growth through investments in equity and equity related securities of predominantly large cap and mid cap stocks.
Growthvine rating: 2/5 — ranked #28 of 41 in category.
Fund basics
| Category | Equity: Large & Mid Cap |
|---|
| NAV | ₹11.74 (as of 2026-10-23) |
|---|
| AUM | ₹777 Cr |
|---|
| Expense ratio | 2.02% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Anandha Padmanabhan Anjeneyan |
|---|
| Exit load | 0.5% for redemption within 90 days |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −16.10% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 96.1% of NIFTY LargeMidcap 250's upside and 90.7% of its downside.
Market cap allocation
| Large cap | 52.5% |
|---|
| Mid cap | 40.4% |
|---|
| Small cap | 7.2% |
|---|
Concentration
| Top 5 holdings | 19.0% |
|---|
| Top 10 holdings | 30.0% |
|---|
| Total holdings | 76 |
|---|
| Index overlap | 42.7% |
|---|
| Active share | 57.3% |
|---|
Top holdings
- ICICI Bank Ltd. — 5.6%
- HDFC Bank Ltd. — 4.5%
- Reliance Industries Ltd — 3.4%
- Larsen & Toubro Limited — 2.9%
- Bharti Airtel Ltd. — 2.6%
- Clearing Corporation of India Ltd. — 2.4%
- Eternal Limited — 2.4%
- State Bank Of India — 2.3%
- Bajaj Finance Limited — 2.2%
- JSW Infrastructure Limited — 2.1%
Top sectors
- Banking & Financial — 17.8%
- Automobile — 9.7%
- Pharma & Biotech — 8.0%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −6.3% | Q2 | #15 of 38 |
| 2025 | 4.5% | Q3 | #19 of 34 |